Literature DB >> 17520345

Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer.

Pavel Elsakov1, Juozas Kurtinaitis, Valerij Ostapenko.   

Abstract

The aim of this prospective study is to assess the prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer. The study group comprised 19 women having multiple primary breast cancers (breast-breast, breast-other primary) who were either BRCA1 mutation carriers, or not. Appearance of a second primary cancer was recognised as the event and survival and second primary free cancer survival was calculated from the date of diagnosis to the secondary primary cancer. The results of this study show that the event free survival of women with familial breast cancer affected by a second primary cancer, who are BRCA1 mutation carriers is better, compared with women from the general population with breast cancer selected for second primary cancer sites and all second primary sites -- P = 0.009 and P = 0.0078 respectively. In contrast, the event free survival of women with breast cancer affected by a second primary cancer, without a breast cancer family history, who are not BRCA1 mutation carriers is the same, as for women from the general population with breast cancer selected for second primary cancer sites and all second primary sites -- P = 0.6417 and P = 0.4859 respectively. The median time from diagnosis of the first to second primary cancer in the mutation carrying, and non-carrying, groups was 8,7 and 1,9 years respectively. In the study group, the highest event free survival rates had been observed among those carrying the said mutations -- 66.7% at 5 years, and 33.3% at 10 years -- in contrast with those not carrying the mutations, with rates of 30.8% and 15.4% respectively.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17520345     DOI: 10.1007/s10689-007-9139-7

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  19 in total

1.  Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families.

Authors:  O Oszurek; B Gorski; J Gronwald; Z Prosolow; K Uglanica; A Murinow; I Bobko; O Downar; M Zlobicz; D Norik; T Byrski; A Jakubowska; J Lubinski
Journal:  Clin Genet       Date:  2001-12       Impact factor: 4.438

2.  Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.

Authors:  J S Lee; S Wacholder; J P Struewing; M McAdams; D Pee; L C Brody; M A Tucker; P Hartge
Journal:  J Natl Cancer Inst       Date:  1999-02-03       Impact factor: 13.506

3.  Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population.

Authors:  K M Lin; M Shashidharan; C A Ternent; A G Thorson; G J Blatchford; M A Christensen; S J Lanspa; S J Lemon; P Watson; H T Lynch
Journal:  Dis Colon Rectum       Date:  1998-04       Impact factor: 4.585

4.  BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.

Authors:  H A Shih; K L Nathanson; S Seal; N Collins; M R Stratton; T R Rebbeck; B L Weber
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

5.  Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility.

Authors:  H S Evans; C M Lewis; D Robinson; C M Bell; H Møller; S V Hodgson
Journal:  Int J Cancer       Date:  2001-12-01       Impact factor: 7.396

6.  High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia.

Authors:  Laima Tikhomirova; Olga Sinicka; Dagnija Smite; Janis Eglitis; Shirley V Hodgson; Aivars Stengrevics
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

7.  High incidence of 4153delA BRCA1 gene mutations in Lithuanian breast- and breast-ovarian cancer families.

Authors:  Jacek Gronwald; Pavel Elsakov; Bohdan Górski; Jan Lubiński
Journal:  Breast Cancer Res Treat       Date:  2005-11       Impact factor: 4.872

8.  A high proportion of founder BRCA1 mutations in Polish breast cancer families.

Authors:  Bohdan Górski; Anna Jakubowska; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Ewa Grzybowska; Andrzej Mackiewicz; Malgorzata Stawicka; Marek Bebenek; Dagmara Sorokin; Łucja Fiszer-Maliszewska; Olga Haus; Hanna Janiszewska; Stanisław Niepsuj; Stanisław Góźdź; Lech Zaremba; Michał Posmyk; Maria Płuzańska; Ewa Kilar; Dorota Czudowska; Bernard Waśko; Roman Miturski; Jerzy R Kowalczyk; Krzysztof Urbański; Marek Szwiec; Jan Koc; Bogusław Debniak; Andrzej Rozmiarek; Tadeusz Debniak; Cezary Cybulski; Elzbieta Kowalska; Aleksandra Tołoczko-Grabarek; Stanisław Zajaczek; Janusz Menkiszak; Krzysztof Medrek; Bartłomiej Masojć; Marek Mierzejewski; Steven Alexander Narod; Jan Lubiński
Journal:  Int J Cancer       Date:  2004-07-10       Impact factor: 7.396

9.  Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations.

Authors:  D K Gaffney; R M Brohet; C M Lewis; J A Holden; S S Buys; S L Neuhausen; L Steele; V Avizonis; J R Stewart; L A Cannon-Albright
Journal:  Radiother Oncol       Date:  1998-05       Impact factor: 6.280

10.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.

Authors: 
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

View more
  1 in total

Review 1.  Clinical and Functional Assays of Radiosensitivity and Radiation-Induced Second Cancer.

Authors:  Mohammad Habash; Luis C Bohorquez; Elizabeth Kyriakou; Tomas Kron; Olga A Martin; Benjamin J Blyth
Journal:  Cancers (Basel)       Date:  2017-10-27       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.